ASH 2021 | Updated results of GRIFFIN: D-RVd vs RVd in patients with newly diagnosed multiple myeloma
Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, updates us on the findings from the Phase II GRIFFIN trial assessing the addition of daratumumab to lenalidomide-bortezomib-dexamethasone (D-RVd) versus lenalidomide-bortezomib-dexamethasone (RVd) alone in patients with newly diagnosed multiple myeloma (NCT02874742). By the end of two years of maintenance therapy, the complete response (CR) rate was 79.8% in the D-RVd group vs 60.8% in the RVd group. Measurable residual disease (MRD) negativity and sustained MRD negativity were also significantly higher in the D-RVd arm. Interestingly, the rates of MRD negativity increased significantly from the end of the first year of maintenance therapy to the second year of maintenance therapy. Moreover, although the data is still premature and statistical significance for progression-free survival (PFS) has not yet been reached, there is a trend towards improved PFS in the daratumumab arm. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Disclosures
Janssen: Other: Advisory Board; Novartis: Consultancy; Oncopeptides: Consultancy, Honoraria; TeneoBio: Other: Advisory Board; Adaptive Biotechnologies: Other: Advisory Board; BMS: Other: Advisory Board; GSK: Honoraria.
